Autopsy report · NCT00226941

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

“The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months after it had already started.
• Ran for about 4 years 8 months before it stopped.
• 23 participants enrolled.
• Results were posted on the registry 8 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

George Albert Fisher

Sponsor type

University, hospital or other

Conditions

Rectal Cancer; Colo-rectal Cancer

Interventions

Cetuximab; Oxaliplatin; Capecitabine; Radiotherapy; Diphenhydramine hydrochloride (HCl)

Participants

23

Sites

1

Countries

United States

Trials that died the same way

• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
  “This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” (69% match in meaning)
• Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
  “The study did not meet efficacy end point and did not enroll patients in the randomized phase.” (64% match in meaning)
• Study of Pemetrexed for Second-Line Pancreas Cancer
  “At interim analysis the study did not meet the response criteria to continue” (64% match in meaning)
• Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
  “After completion of Phase I, it was decided not to initiate Phase II of the study.” (64% match in meaning)
• A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
  “While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.